Results 81 to 90 of about 19,166 (184)

Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

Терапевтический архив
Aim. To evaluate the hematological response within 4 weeks of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to long-term eculizumab therapy. Materials and methods.
Olesya U. Klimova, Irina K. Golubovskaya, Yuriy N. Kuznetsov, Maria V. Marchenko, Alexander D. Kulagin   +4 more
doaj   +1 more source

Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice [PDF]

, 2014
Sepsis and septic shock, caused by an excessive systemic host-inflammatory response, are associated with high morbidity and mortality. The complement system and TLRs provide important pattern recognition receptors initiating the cytokine storm by ...
Sandanger, Øystein,, Pischke, Søren E,, Nilsson, Per H., Barratt-Due, Andreas, Sandanger, Øystein, Gaus, Wilhelm,, Gaus, Wilhelm, Espevik, Terje, Espevik, Terje,, Nilsson, Per H.,, Denk, Stephanie, Pischke, Søren E., Mollnes, Tom E., Nunn, Miles A,, Barratt-Due, Andreas,, Denk, Stephanie,, Mollnes, Tom E,, Huber-Lang, Markus, Nunn, Miles A., Huber-Lang, Markus,   +19 more
core   +1 more source

Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy

Oncohematology
The introduction of the complement component C5 inhibitor eculizumab has radically changed the prognosis and quality of life of patients with paroxysmal nocturnal hemoglobinuria. Up to 30 % of patients develop only a suboptimal response to C5 inhibition.
M. V. Marchenko, O. U. Klimova, E. V. Anikina, A. V. Lapina, T. A. Rudakova, T. I. Ksenzova, A. D. Kulagin   +6 more
openaire   +2 more sources

Inhibition of the complement component C5 and the Toll-like receptor molecule CD14 prevents systemic and local kidney inflammation in mice experiencing brain death

Scientific Reports
Brain death (BD) induces a systemic inflammation impairing donor organ quality. Complement and Toll-like receptors (TLRs), with the key co-receptor CD14 molecule, are key innate recognition immune systems.
Tom E. Mollnes, Neeltina M. Jager, Petra J. Ottens, Camilla Schjalm, Zwanida J. Veldhuis, Henri G. D. Leuvenink, Søren E. Pischke   +6 more
doaj   +1 more source

Secreted Aspergillus fumigatus protease Alp1 degrades human complement proteins C3, C4, and C5

, 2010
The opportunistic human pathogenic fungus Aspergillus fumigatus is a major cause of fungal infections in immunocompromised patients. Innate immunity plays an important role in the defense against infections.
Peter F. Zipfel, Susann Schindler, Marcel Thoen, Ilse D. Jacobsen, Judith Behnsen, Axel A. Brakhage, Dirk Wartenberg, Franziska Lessing   +7 more
core   +1 more source

PNH TREATMENT: TREATMENTS OF TODAY AND TOMORROW

Hematology, Transfusion and Cell Therapy
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder characterized by chronic destruction of red blood cells (hemolytic anemia) and blood clots (thrombosis).1 PNH can occur at any age, although it is most often diagnosed in young ...
Zeynep Tuğba Güven
doaj   +1 more source

FACIN, a double-edged sword of the emerging periodontal pathogen Filifactor alocis : a metabolic enzyme moonlighting as a complement inhibitor

, 2016
Periodontal disease is one of the most common inflammatory infectious diseases worldwide and it is associated with other syndromes, such as cardiovascular disease or rheumatoid arthritis.
Miedziak, Beata,, Magda, Michal, Blom, Anna M, Potempa, Jan, Potempa, Jan,, King, Ben C., Jusko, Monika, Magda, Michal,, King, Ben C.,, Miedziak, Beata, Blom, Anna M., Bielecka, Ewa, Bielecka, Ewa,, Ermert, David,, Jusko, Monika,, Magda, Michał, Ermert, David, Blom, Anna M.,, Riesbeck, Kristian,, King, Ben C, Lund University., Riesbeck, Kristian, Eick, Sigrun,, Eick, Sigrun   +23 more
core   +1 more source

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study. [PDF]

J Blood Med, 2022
Shammo J, Gajra A, Patel Y, Tomazos I, Kish J, Hill A, Sierra JR, Araten D.   +7 more
europepmc   +1 more source

A Novel C5 Complement Inhibitor Protects Against Sepsis-Induced Activation of Complement, Coagulation and Inflammation and Provides Survival Benefit in E. coli Sepsis

Blood, 2014
Abstract Bacterial sepsis triggers robust early activation of the complement system that leads to the formation of the C5b-9 terminal complex (TCC) and potent proinflammatory anaphylatoxins, C3a and C5a, which significantly contribute to organ failure and death.
Ravi Keshari, Robert Silasi-Mansat, Narcis I. Popescu, Hala Chaaban, Cristina Lupu, Steven J DeMarco, Florea Lupu   +6 more
openaire   +1 more source

A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein [PDF]

, 2018
International audienceThe complement system is an efficient anti-microbial effector mechanism. On the other hand abnormal complement activation is involved in the pathogenesis of multiple inflammatory and hemolytic diseases.
Nicolas S. Merle, Merle, Nicolas S., Peter Kristensen, Roumenina, Lubka T, Yatime, Laure, Lubka T. Roumenina, Andersen, Gregers R, Østergaard, Jakob, Andersen, Gregers, Østergaard, Jakob A, Jakob A. Østergaard, Hansen, Annette G, Hansen, Annette G., Niels Anton Friis, Bjerre, Mette, Kristensen, Peter; id_orcid, Steffen Thiel, Gregers R. Andersen, Mette Bjerre, Friis, Niels Anton, Thiel, Steffen, Merle, Nicolas S, Roumenina, Lubka, Laure Yatime, Annette G. Hansen, Kristensen, Peter   +25 more
core   +1 more source